Published on : Jun 13, 2016
ALBANY, New York, June 13, 2016 – ResearchMoz.us has announced the addition Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2022 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market,” a new report, to their offering. This study presents a detailed analysis of vital aspects of the market. It also includes a market snapshot highlighting the key technological advancements currently taking place or projected to take place in the market between 2015 and 2022. In addition, the key upcoming opportunities within non-small cell lung cancer therapeutics in the five Asia Pacific markets, namely, China, India, Australia, Japan, and South Korea have also been presented under this study. Factors such as the impact of patent expiration on the presently branded therapies and the performance of late-stage therapies in clinical trials within Asia Pacific have also been detailed in this report.
The NSCLC market in Asia Pacific was pegged at $2.7 bn in 2015 and is predicted to touch $4.9 bn in 2022, by expanding at an 8.70% CAGR between 2015 and 2022. The introduction section of the report starts by presenting the disease overview including the epidemiology and symptoms. Non-small cell lung cancer (NSCLC) is the most common kind of lung cancer – 85% of lung cancers globally are reportedly NSCLCs. Adenocarcinoma, large cell carcinoma, and squamous cell carcinoma are the key sub-types of NSCLC. As a class, this type of cancer is relatively insensitive to chemotherapy as compared to small cell cancer.
NSCLC is primarily treated by utilizing surgical resection coupled with curative intent. However, pre-operatively and post-operatively, chemotherapy is also being utilized for treating this type of cancer. Globally, over 50% of the cases of NSCLC are diagnosed in individuals who are more than 65 years old. As stated in the report, the poor prognosis, especially in patients with advanced disease, has resulted in the growing requirement for enhanced therapeutic options in the region of Asia Pacific.
Click here to get more info with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=725317
The next part of the report highlights the treatment options and guidelines. This section elaborates upon the treatment algorithm, maintenance therapy, first-line, second-line, and third-line treatments, and adjuvant therapy. The marketed and pipeline products in the NSCLC market in Asia Pacific have also been highlighted in this section. At present, individuals with non-squamous histology may undergo treatment with effective therapies such as Alimta. On the other hand, the individuals having activating mutations in ALK or EFFR are prescribed a number of targeted therapies such as Iressa, Tarceva, Gilotrif, and Xalkori.
Opdivo, a mAb immune checkpoint inhibitor utilized for PD 1, has recently entered and gained approval in the market for the treatment of metastatic squamous NSCLC patients within Japan and Australia in 2015 and 2016, respectively.
In the following section, the study throws light on the key drivers and inhibitors in the Asia Pacific NSCLC market. The increasing passive smoking and pollution and the rising aging population within Asia Pacific are amongst the major factors fuelling the growth of the market here. The proliferation of first and second-line therapy options and the rising mutation testing in Asia Pacific will also stimulate the development of the market.
Furthermore, the expansion in the health insurance systems and the increasing healthcare reforms in Asia Pacific will also impact the market positively. On the other hand, the soaring prices of therapeutics and the branded therapies’ patent expiration will impede the growth of the market in Asia Pacific. In addition, the increasing introduction of generic drugs may impact the market negatively. The key players dominant in the market are Bristol-Myers Squibb, OncoGenex, Peregrine Pharmaceuticals, and AstraZeneca, among others.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on [email protected]